Investment Case Summary
- ANSTO validated the full flowsheet at 98% NdPr extraction, improving as the test scale grew.
- Final MREC is independently certified non-radioactive, cutting logistics cost and widening the customer pool.
- Execution at the Kazakhstan SARECO plant into Q4 2026 is now the only meaningful risk left.
ANSTO signs off the full flowsheet and clears the Kazakhstan plant to run Kangankunde concentrate at commercial scale
Lindian Resources (ASX:LIN) has closed out one of the last technical hurdles standing between Kangankunde and commercial rare earth production. ANSTO, Australia’s national nuclear agency, has independently validated the complete sulphuric acid flowsheet from monazite concentrate through to specification mixed rare earth carbonate (MREC), which is the intermediate product that separation plants and magnet makers actually pay for.
The headline number is a 98% NdPr extraction rate at the largest test scale the program ran, up from 97% at the earlier optimisation stage. Performance improved as batch size increased, which is unusual and important. Most hydrometallurgical flowsheets get worse when you scale them, not better.
The second, quieter result is that ANSTO has certified the final MREC as exempt from radioactive transport and handling under IAEA rules. Uranium, thorium and every decay-chain radionuclide the lab looked for, including the commercially sensitive Actinium-227, came back below detection limits. For a company targeting first production at the Kazakhstan MREC facility this quarter, the timing is not coincidence.
- Updated
- INSIDER CONVICTION TRADES FY26
The market hasn't noticed yet.
Disclosed by law. Missed by most investors. 129 trades tracked by us.
NO Credit card
- Director buys & sells tracked
- Buy / Hold / Sell verdict on every stock
- Technical analysis included
Why the 98% number matters more than the 97% one it replaced
The jump from 97% to 98% NdPr extraction sounds trivial. It is not, because of where in the program it happened.
The earlier 97% number came from bench-scale optimisation. Today’s 98% came from a much larger bulk test designed to feed the downstream circuit end-to-end. Extraction improved rather than degraded during scale-up, and the pregnant leach solution reached 21.1 g/L TREY, the strongest tenor the program produced.
Higher solution tenor is a cost story. Downstream equipment is sized to solution volume, so a richer feed means smaller tanks, less water, less reagent and more throughput through the same plant. Feeding the existing SARECO circuit in Kazakhstan at these tenors means more finished MREC out the door without spending capital on bigger equipment.
The radionuclide certification is the real competitive moat
Typical monazite concentrates carry roughly 0.5% uranium and 4 to 7% thorium. Kangankunde ships with 0.06% thorium and negligible uranium. That gap is the whole reason the ANSTO work matters commercially, not just technically.
Projects that process ordinary monazite have to build dedicated uranium and thorium removal circuits, run specialised storage, and handle the product as a Class 7 radioactive hazard from mine gate to customer. ANSTO has now certified that Kangankunde MREC does not need any of that. Ac-227 came in more than an order of magnitude below regulatory significance, which is the single number downstream processors watch most closely.
We think this is the piece of the story the market has been slowest to price. A non-radioactive MREC is a shorter, cheaper, easier product to sell into separation plants and magnet manufacturers, particularly customers that will not touch traditional monazite streams at all.
From pilot validation to actually running the Kazakhstan plant
The ANSTO program is now complete. The next milestone is operational, not technical. Lindian has to recommission the SARECO hydromet plant, feed it Kangankunde concentrate, and produce specification MREC at commercial rates.
Management has been guiding to first production in Q4 2026, roughly a single quarter away from today. The company is fully funded for Stage 1 after the A$100 million placement in April, and the Iluka strategic partnership underpins offtake and funding on the concentrate side. So the funding overhang that dogs most pre-production rare earth developers is not the risk here.
The risk is execution at SARECO. An operating plant is not the same as a validated flowsheet, and the ramp from first feed to nameplate is where hydromet projects historically lose 6 to 12 months.
The Investors Takeaway for Lindian Resources
Lindian has now closed out the technical case for Kangankunde. The recoveries are proven at scale, the radionuclide profile is genuinely differentiated and independently certified, and the downstream flowsheet slots into an existing plant with an existing acid supply contract. That is a materially stronger technical position than most ASX-listed rare earth developers can point to at the same stage.
The work from here shifts to whether SARECO can be brought up on Kangankunde feed inside the Q4 2026 window and whether MREC volumes ramp on the schedule management has signalled. We would want to see the first commissioning update inside the September quarterly, along with any offtake pricing colour Iluka is prepared to disclose. Our previous coverage of ASX critical minerals names dealing with regulatory and permitting overhangs sits at stocksdownunder.
The technical de-risking is done. The operational proof is the next test, and it arrives on a very short clock.
